N-Mercaptoacetyl-L-histidine

Cat. No.: HY-182457: Data Sheet Handling Instructions
FAQs
Technical Support

N-Mercaptoacetyl-L-histidine is an angiotensin-converting enzyme (ACE) inhibitor with a target pIC₅₀ of 3.59 M.N-Mercaptoacetyl-L-histidine binds to the zinc-containing active site of ACE, which mediates conversion of angiotensin I to angiotensin II.N-Mercaptoacetyl-L-histidine can be used for the research of hypertension.

For research use only. We do not sell to patients.

N-Mercaptoacetyl-L-histidine Chemical Structure

CAS No. : 62404-82-4

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	N-Mercaptoacetyl-L-histidine is an angiotensin-converting enzyme (ACE) inhibitor with a target pIC₅₀ of 3.59 M.N-Mercaptoacetyl-L-histidine binds to the zinc-containing active site of ACE, which mediates conversion of angiotensin I to angiotensin II.N-Mercaptoacetyl-L-histidine can be used for the research of hypertension^[1].
In Vitro	N-Mercaptoacetyl-L-histidine (THIOL12) is an angiotensin-converting enzyme (ACE) inhibitor with a target pIC₅₀ of 3.59 M^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. N-Mercaptoacetyl-L-histidine Related Antibodies
Molecular Weight	229.26
Formula	C₈H₁₁N₃O₃S
CAS No.	62404-82-4
SMILES	SCC(N[C@H](C(O)=O)CC1=CN=CN1)=O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (268 KB) Handling Instructions (2659 KB)
References	[1]. Waller CL, et al. Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and complementary-receptor-field alignment rules. J Med Chem. 1993;36(16):2390-2403.